Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2019 View  |  Download
Durvalumab in combination with Tremelimumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Head and neck cancer Head and Neck Cancer 2018 View  |  Download
Durvalumab in combination with Tremelimumab for locally advanced or metastatic urothelial bladder cancer – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2017 View  |  Download
Durvalumab in combination with Tremelimumab and Standard of Care Chemotherapy for EGFR Negative, ALK Negative Metastatic NSCLC– First Line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2018 View  |  Download
Durvalumab in combination with tremelimumab and chemotherapy for unresectable, locally advanced or metastatic urothelial cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206) Bladder cancer Urological Cancer 2020 View  |  Download
Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
Durvalumab in addition to gemcitabine and cisplatin for advanced biliary tract cancer – first line Cisplatin (Platinol) , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Gemcitabine (Gemzar; gemcitabine hydrochloride) Biliary tract cancer Gastrointestinal Cancer 2021 View  |  Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2019 View  |  Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Head and neck cancer Head and Neck Cancer 2019 View  |  Download
Durvalumab for previously untreated,hepatocellular carcinoma Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2021 View  |  Download
1 2 83 84 85 86 87 117 118
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications